Daniel Wallace

Dec 6, 2023 | hcplive.com | Nehad Soloman |Andrew Sharobeem |Daniel Wallace

0:00 Introduction 1:25 LN and its prognosis 3:20 Challenges due to varied presentations of LN 4:10 Traditional treatment paradigms 6:45 Challenges with management of LN 8:25 Classification of LN and its role in treatment 12:00 New treatments in LN 17:50 Anti-CD20 for treatment of LN 21:00 Combination therapy in clinical practice 22:45 Multidisciplinary care for LN 23:50 Guidelines in LN 26:00 Kidney biopsy in LN 27:15 Biomarkers for LN 28:30 Clinical outcomes in LN 31:30 JAK inhibitors in...

Jun 22, 2023 | futuremedicine.com | Xavier Montalban |Daniel Wallace |Mark C Genovese |Davorka Tomic

Neurodegenerative Disease ManagementAhead of PrintPlain Language Summary of PublicationOpen AccessAbstractWhat is this summary about? This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS).